Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Inclusion Criteria (All patients): * Confirmed Advanced Unresectable Solid Tumor * Measurable disease by RECIST 1.1 by CT or MRI * Documented disease progression on or following last line of therapy * Archival tumor sample for submission * ECOG performance status 0 or 1 * Resolution of all acute, reversible toxic effects of prior therapy or surgical procedures to at least grade 1 (except alopecia and peripheral neuropathy to at least grade 2) * Adequate organ function * A limited number of patients enrolled in Dose Escalation may be required to agree to pre- and on-treatment tumor biopsies Inclusion Criteria (Dose Expansion patients only) * LIF- High NSCLC, Ovarian Cancer, or Pancreatic Cancer for the tumor-specific cohorts or Advanced Solid Tumor for the basket cohort as assessed by tumor tissue evaluation by IHC * All patients enrolled in Dose Expansion must agree to undergo pre- and on-treatment tumor biopsies Exclusion Criteria (All Patients): * Systemic anti-cancer therapy within 4 weeks or 5 half-lives prior to study entry * Previous or concurrent malignancy that could affect compliance with protocol or interpretation of results * Clinically significant, unstable cardiovascular or pulmonary disease as specified in detail in the study protocol * History of acquired or congenital immunodeficiency syndrome or receiving immunosuppressive therapy * Uncontrolled infections or serologically positive HIV or hepatitis B or C infection * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or interfere with interpretation of study results